Skip to content
2000
Volume 21, Issue 23
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

There is a high rate of benzodiazepine use in the population. Benzodiazepines are used for multiple indications (anxiety, seizures, alcohol withdrawal, muscular relaxation and anesthesia). Benzodiazepines are also addictive substances and a non-negligible fraction of regular users will develop dependence. There is currently no approved pharmacotherapy for benzodiazepine use disorder treatment and optimal strategies for treatment are unclear. In this review, we aimed to summarize the findings on off-label pharmacologic therapy that have been used for BZD dependence. One classical approach is to provide a slow taper associated with counseling. Anti-epileptic drugs appear also to alleviate symptoms of withdrawal. The long-term strategies of maintenance therapy (with benzodiazepine) or of blocking therapy (with a GABA antagonist such as flumazenil) could provide some clinical benefit but have not yet been tested appropriately. Pregabalin appears promising and deserves further investigation. There is a clear need for more clinical trials in this area to improve care.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612821666150619092039
2015-07-01
2025-01-10
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612821666150619092039
Loading

  • Article Type:
    Research Article
Keyword(s): Agonist; benzodiazepine; dependence; medication; off-label; pregabalin; replacement; treatment
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test